Clover Biopharma's Respiratory Illness Vaccines Show Promise in Phase II Australian Trials

MT Newswires Live

Sep 07

Clover Biopharmaceuticals (HKG:2197) has disclosed positive results from its phase 2 Australia trials evaluating two vaccine combinations to potentially treat respiratory illnesses in adults, according to a Hong Kong Exchange filing from Monday.

The company said the groups receiving the combinations SCB-1022 and SCB-1033 saw the rate of respiratory tract infection decline by 62% when compared to placebo. The combinations were generally well tolerated, with side effects including fatigue, headache, and pain at the injection site.

Clover also said it increased production of the vaccine candidates during the trial, which it believes will help with late-stage testing and commercialization. Based on the latest trial results, the company plans further testing and is seeking partners for a global collaboration.

The company's shares were up nearly 2% in afternoon trading on the HKEX.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/news/2665394100"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2665394100\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2665394100?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-07 14:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665394100","market":"nz","top_or_hot":-1,"title":"Clover Biopharma's Respiratory Illness Vaccines Show Promise in Phase II Australian Trials","media":"MT Newswires Live","content":"<html><body><p> Clover Biopharmaceuticals (HKG:2197) has disclosed positive results from its phase 2 Australia trials evaluating two vaccine combinations to potentially treat respiratory illnesses in adults, according to a Hong Kong Exchange filing from Monday.</p><p>The company said the groups receiving the combinations SCB-1022 and SCB-1033 saw the rate of respiratory tract infection decline by 62% when compared to placebo. The combinations were generally well tolerated, with side effects including fatigue, headache, and pain at the injection site.</p><p>Clover also said it increased production of the vaccine candidates during the trial, which it believes will help with late-stage testing and commercialization. Based on the latest trial results, the company plans further testing and is seeking partners for a global collaboration.</p><p>The company's shares were up nearly 2% in afternoon trading on the HKEX.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharma's Respiratory Illness Vaccines Show Promise in Phase II Australian Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharma's Respiratory Illness Vaccines Show Promise in Phase II Australian Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-07 14:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Clover Biopharmaceuticals (HKG:2197) has disclosed positive results from its phase 2 Australia trials evaluating two vaccine combinations to potentially treat respiratory illnesses in adults, according to a Hong Kong Exchange filing from Monday.</p><p>The company said the groups receiving the combinations SCB-1022 and SCB-1033 saw the rate of respiratory tract infection decline by 62% when compared to placebo. The combinations were generally well tolerated, with side effects including fatigue, headache, and pain at the injection site.</p><p>Clover also said it increased production of the vaccine candidates during the trial, which it believes will help with late-stage testing and commercialization. Based on the latest trial results, the company plans further testing and is seeking partners for a global collaboration.</p><p>The company's shares were up nearly 2% in afternoon trading on the HKEX.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GEAR.AU","symbol_name":"BETASHARES GEARED AUS EQTY F","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2665394100","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2665394100","pubTimestamp":1788762559,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clover Biopharmaceuticals  has disclosed positive results from its phase 2 Australia trials evaluating two vaccine combinations to potentially treat respiratory illnesses in adults, according to a Hong Kong Exchange filing from Monday.The company said the groups receiving the combinations SCB-1022 and SCB-1033 saw the rate of respiratory tract infection decline by 62% when compared to placebo. The combinations were generally well tolerated, with side effects including fatigue, headache, and pain at the injection site.Clover also said it increased production of the vaccine candidates during the trial, which it believes will help with late-stage testing and commercialization. Based on the latest trial results, the company plans further testing and is seeking partners for a global collaboration.The company's shares were up nearly 2% in afternoon trading on the HKEX.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GEAR.AU":"BETASHARES GEARED AUS EQTY F","E200.AU":"SPDR S&P/ASX 200 ESG FUND","GIVE.AU":"PERPETUAL ESG AU SHR EQMF","BBOZ.AU":"BETASHARES AUSTRALIAN STRONG BEAR (HEDGE FUND)","STW.AU":"SPDR® S&P/ASX 200 ETF","QFN.AU":"BetaShares Australian Fincls Sect ETF","IOZ.AU":"iShares Core S&P/ASX 200","QRE.AU":"BetaShares Australian Res Sect ETF","XAO.AU":"标普/澳交所 普通股指数","SLF.AU":"SPDR S&P/ASX 200 LISTED PROP","BEAR.AU":"BETASHARES AUS EQ BEAR HF","DACE.AU":"DIMENSIONAL AUST CORE EQ","VAP.AU":"VANGUARD AU PROP SEC IDX ETF","BK1161":"生物科技","02197":"三叶草生物-B","XJO.AU":"标普/澳交所 200指数","ZYAU.AU":"Etfs S&p/asx 300 High Yield Plus Etf","VAS.AU":"VANGUARD AUST SHARES IDX ETF","XKO.AU":"标普/澳交所 300指数","OZF.AU":"SPDR S&P/ASX 200 FINANCIALS","IMLC.AU":"INV MUTUAL CONC AUS SHAR ETF","EIGA.AU":"EINVEST INCOME GENERATOR FD","OZR.AU":"SPDR S&P/ASX 200 RESOURCES F","IIGF.AU":"Intelligent Investor Australian Equity Growth Fund (Managed Fund)","IISV.AU":"INTELL INV SELVAL SHR FD MF"},"translate_title":"Clover Biopharma 的呼吸道疾病疫苗在澳大利亚二期试验中显示出前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QFN.AU":0.6,"XKO.AU":1.5,"IIGF.AU":0.6,"XAO.AU":1.5,"OZR.AU":0.6,"BBOZ.AU":0.6,"IISV.AU":0.6,"02197":1,"IOZ.AU":0.6,"DACE.AU":0.6,"GEAR.AU":0.6,"SLF.AU":0.6,"QRE.AU":0.6,"OZF.AU":0.6,"VAS.AU":0.6,"BEAR.AU":0.6,"E200.AU":0.6,"STW.AU":0.6,"XJO.AU":1.5,"IMLC.AU":0.6,"EIGA.AU":0.6,"ZYAU.AU":0.6,"GIVE.AU":0.6,"VAP.AU":0.6},"content_text":"Clover Biopharmaceuticals (HKG:2197) has disclosed positive results from its phase 2 Australia trials evaluating two vaccine combinations to potentially treat respiratory illnesses in adults, according to a Hong Kong Exchange filing from Monday.The company said the groups receiving the combinations SCB-1022 and SCB-1033 saw the rate of respiratory tract infection decline by 62% when compared to placebo. The combinations were generally well tolerated, with side effects including fatigue, headache, and pain at the injection site.Clover also said it increased production of the vaccine candidates during the trial, which it believes will help with late-stage testing and commercialization. Based on the latest trial results, the company plans further testing and is seeking partners for a global collaboration.The company's shares were up nearly 2% in afternoon trading on the HKEX.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}